Neuvotion Raised Over $1M in Seed Funding to Commercialize Neurostimulation Technology

An early-stage medical device company Neuvotion, Inc., is developing neurostimulation products for the rehabilitation and physical therapy markets. The company received over $1M in seed funding.


The Long Island Angel Network, a group of individual angel investors based on Long Island, and the Good Shepherd Rehabilitation Network, a rehabilitation leader, have provided the company with its first equity investment. Neuvotion will use this funding to expand its team, conduct a multi-site clinical study, and seek FDA clearance for its initial product.

The company is developing solutions for facilitating and restoring movement to the millions of patients experiencing impairment from stroke, traumatic injury, and other conditions. Its NeuStim™ technology combines highly targeted neurostimulation and artificial intelligence to make physical and occupational therapy more effective and efficient. Neuvotion is planning a multi-site clinical study to begin next year.

Neuvotion also secured exclusive worldwide rights to transformative technology developed by its founder, Chad Bouton. He is a professor at the Feinstein Institutes for Medical Research at Northwell Health.

"I am inspired by the prospect of helping the millions of patients who have experienced a stroke, traumatic injury, or are living with movement impairment, to reach their goals," said Chad Bouton, Founder & CEO of Neuvotion. "We are working to commercialize NeuStim and other technologies so they can be used in clinical practice, and ultimately in the home to increase the quality of life and independence."